In EGFR mutation‐positive (EGFRm+) advanced NSCLC patients, first/second‐generation EGFR tyrosine kinase inhibitors (TKIs) have been demonstrated to prolong progression‐free survival (PFS) compared to cytotoxic agents.4, 5, 6. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.